Clarity Pharmaceuticals has added 64/67Cu-SAR-trastuzumab to its Targeted Copper Theranostic (TCT) portfolio, strengthening ...

Shanghai Henlius Biotech, Inc. (“Henlius”) announced FDA acceptance of the Biologics License Application (BLA) for ...

Shanghai Henlius Biotech, Inc. (2696.HK) today announced it has entered into a license agreement with Dr. Reddy's Laboratories SA, wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd., (BSE: ...

Tambe said the company, a subsidiary of the Bengaluru-based Biocon Ltd, has five products in the pipeline for launch in the ...

There is market share gain compared to last year. Any biosimilar might be able to take on a four-five or six player market, ...

Avtozma, the third biosimilar to Actemra, has received FDA approval for multiple inflammatory diseases and COVID-19, ...

JERSEY CITY, NJ, USA I January 30, 2025 I Celltrion today announced that the U.S. Food and Drug Administration (FDA) has approved AVTOZMA® (CT-P47, ...

In Budget 2024, the government slashed GST (Goods and Services Tax) from three major cancer drugs: Trastuzumab Deruxtecan, ...

While GST on some cancer drugs like Trastuzumab was reduced to 5% from ... For India to remain a global leader in generics and biosimilars while expanding its footprint in novel drug discovery ...

Surveying the next 12 months, J&J expects to chart roughly 3% sales growth to $91.3 billion in 2025 by “overcoming headwinds associated with U.S. biosimilar entries for Stelara,” as well as ...

Additionally, a filgrastim biosimilar (Nypozi; filgrastim-txid) was quietly approved in June 2024. 23 Lastly, Hercessi (trastuzumab-strf) also joined the ranks, becoming the sixth biosimilar ...

The patients were randomly assigned to receive adjuvant treatment with T-DM1 at 3.6 mg/kg (n=743) or trastuzumab at 6 mg/kg (n=743) every 3 weeks for 14 cycles. Baseline characteristics were ...